Atyr PHARMA INC (NASDAQ:ATYR) Director Acquires $15,000.00 in Stock

Atyr PHARMA INC (NASDAQ:ATYR - Get Free Report) Director Jane A. Gross acquired 3,750 shares of the stock in a transaction dated Monday, March 17th. The stock was acquired at an average cost of $4.00 per share, with a total value of $15,000.00. Following the purchase, the director now owns 9,750 shares of the company's stock, valued at approximately $39,000. This trade represents a 62.50 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Atyr PHARMA Stock Performance

ATYR stock traded down $0.08 on Friday, hitting $3.68. The company's stock had a trading volume of 819,703 shares, compared to its average volume of 844,513. The stock has a market cap of $327.00 million, a price-to-earnings ratio of -3.91 and a beta of 0.98. The firm has a 50 day moving average of $3.66 and a two-hundred day moving average of $3.11. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.02. Atyr PHARMA INC has a 1 year low of $1.42 and a 1 year high of $4.66.

Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last announced its earnings results on Thursday, March 13th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.05. Equities analysts predict that Atyr PHARMA INC will post -0.91 EPS for the current fiscal year.

Remove Ads

Hedge Funds Weigh In On Atyr PHARMA

Several institutional investors have recently bought and sold shares of ATYR. JPMorgan Chase & Co. boosted its holdings in shares of Atyr PHARMA by 52.0% in the third quarter. JPMorgan Chase & Co. now owns 31,440 shares of the company's stock valued at $55,000 after acquiring an additional 10,754 shares in the last quarter. Kingswood Wealth Advisors LLC purchased a new stake in Atyr PHARMA in the 4th quarter valued at approximately $170,000. Alterna Wealth Management Inc. acquired a new position in Atyr PHARMA during the 4th quarter worth approximately $36,000. D.A. Davidson & CO. acquired a new position in Atyr PHARMA during the 4th quarter worth approximately $141,000. Finally, Charles Schwab Investment Management Inc. purchased a new position in Atyr PHARMA in the fourth quarter worth $144,000. 61.72% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Cantor Fitzgerald initiated coverage on shares of Atyr PHARMA in a research report on Monday, January 6th. They issued an "overweight" rating for the company. Leerink Partners began coverage on Atyr PHARMA in a report on Tuesday, February 18th. They set an "outperform" rating and a $16.00 price target on the stock. Leerink Partnrs upgraded Atyr PHARMA to a "strong-buy" rating in a research note on Tuesday, February 18th. Finally, HC Wainwright restated a "buy" rating and set a $35.00 target price on shares of Atyr PHARMA in a research note on Friday, March 14th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $18.60.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.